Therapeutic prospects for the prevention of neurodegeneration Huntington's disease and the polyglutamine repeat disorders

被引：4
作者：
Kimura, Yoko
Lee, Wyan-Ching Mimi
Littleton, J. Troy
机构：
[1] MIT, Picower Inst Learning & Memory, Dept Biol, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA
[2] Tokyo Metropolitan Inst Med Sci, Lab Frontier Sci, Bunkyo Ku, Tokyo 1138613, Japan
来源：
MINI-REVIEWS IN MEDICINAL CHEMISTRY | 2007年 / 7卷 / 01期
关键词：
axonal transport; neurodegeneration; vesicle trafficking; protein aggregation; polyQ; Huntington's disease;
D O I：
10.2174/138955707779317867
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
Huntington's disease (HD) is a dominantly inherited neurodegenerative disorder caused by expansion of a polyglutamine (polyQ) tract in the huntingtin protein, resulting in intracellular aggregate formation and neurodegeneration. Biochemical pathways leading from polyQ expansion to disease pathogenesis are largely unknown. Recent approaches using genetic models systems have begun to uncover nuclear and cytoplasmic pathologies that represent potential targets for therapeutic intervention.
引用
收藏
页码：99 / 106
页数：8
相关论文
共 73 条
[1]   Identification of combinatorial drug regimens for treatment of Huntington's disease using Drosophila [J].
Agrawal, N ;
Pallos, J ;
Slepko, N ;
Apostol, BL ;
Bodai, L ;
Chang, LW ;
Chiang, AS ;
Thompson, LM ;
Marsh, JL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (10) :3777-3781
[2]   A cell-based screen for drugs to treat Huntington's disease [J].
Aiken, CT ;
Tobin, AJ ;
Schweitzer, ES .
NEUROBIOLOGY OF DISEASE, 2004, 16 (03) :546-555
[3]   Creatine increases survival and delays motor symptoms in a transgenic animal model of Huntington's disease [J].
Andreassen, OA ;
Dedeoglu, A ;
Ferrante, RJ ;
Jenkins, BG ;
Ferrante, KL ;
Thomas, M ;
Friedlich, A ;
Browne, SE ;
Schilling, G ;
Borchelt, DR ;
Hersch, SM ;
Ross, CA ;
Beal, MF .
NEUROBIOLOGY OF DISEASE, 2001, 8 (03) :479-491
[4]   Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death [J].
Arrasate, M ;
Mitra, S ;
Schweitzer, ES ;
Segal, MR ;
Finkbeiner, S .
NATURE, 2004, 431 (7010) :805-810
[5]   p53 mediates cellular dysfunction and behavioral abnormalities in Huntington's disease [J].
Bae, BI ;
Xu, H ;
Igarashi, S ;
Fujimuro, M ;
Agrawal, N ;
Taya, Y ;
Hayward, SD ;
Moran, TH ;
Montell, C ;
Ross, CA ;
Snyder, SH ;
Sawa, A .
NEURON, 2005, 47 (01) :29-41
[6]   Impairment of the ubiquitin-proteasome system by protein aggregation [J].
Bence, NF ;
Sampat, RM ;
Kopito, RR .
SCIENCE, 2001, 292 (5521) :1552-1555
[7]   Evidence for proteasome involvement in polyglutamine disease:: localization to nuclear inclusions in SCA3/MJD and suppression of polyglutamine aggregation in vitro [J].
Chai, YH ;
Koppenhafer, SL ;
Shoesmith, SJ ;
Perez, MK ;
Paulson, HL .
HUMAN MOLECULAR GENETICS, 1999, 8 (04) :673-682
[8]  
Chai YH, 1999, J NEUROSCI, V19, P10338
[9]   Polyglutamine aggregation behavior in vitro supports a recruitment mechanism of cytotoxicity [J].
Chen, S ;
Berthelier, V ;
Yang, W ;
Wetzel, R .
JOURNAL OF MOLECULAR BIOLOGY, 2001, 311 (01) :173-182
[10]   Chaperone suppression of aggregation and altered subcellular proteasome localization imply protein misfolding in SCA1 [J].
Cummings, CJ ;
Mancini, MA ;
Antalffy, B ;
DeFranco, DB ;
Orr, HT ;
Zoghbi, HY .
NATURE GENETICS, 1998, 19 (02) :148-154
12345678